The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.
Open accessAbstract
Mutations in the p53 gene are most frequent in cancer. Many p53 mutants possess transforming activity in vitro. In cells transformed by such mutants, the mutant protein is oligomerized with endogenous cell p53. To determine the relevance of oligomerization for transformation, miniproteins containing C-terminal portions of p53 were generated. These miniproteins, although carrying no point mutation, transformed at least as efficiently as full-length mutant p53. Transforming activity was coupled with the ability to oligomerize with wild-type p53, as well as with the ability to abrogate sequence-specific DNA binding by coexpressed wild-type p53. These findings suggest that p53-mediated transformation may operate through a dominant negative mechanism, involving the generation of DNA binding-incompetent oligomers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Self-citationIdentification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Cited by
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
p53 is regulated by the lysine demethylase LSD1
Huang, J., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., et al. (2007) · Nature · doi:10.1038/nature06092 · Cited by 807
Rapid Destruction of Human Cdc25A in Response to DNA Damage
Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., & Lukas, J. (2000) · Science · doi:10.1126/science.288.5470.1425 · Cited by 787
Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis
Bennett, M., Macdonald, K., Chan, S.-W., Luzio, J. P., Simari, R., & Weissberg, P. (1998) · Science · doi:10.1126/science.282.5387.290 · Cited by 754
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Central role of p53 in the suntan response and pathologic hyperpigmentation
Cui, R., Widlund, H. R., Feige, E., Lin, J. Y., Wilensky, D. L., Igras, V. E., D'Orazio, J., Fung, C. Y., Schanbacher, C. F., Granter, S. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.045 · Cited by 657
“dominant-negative p53 allele (p53DD; Shaulian et al., 1992) into the PAM212 keratinocyte line and into the human primary foreskin keratinocytes (HFK) ‘‘PAMDD’’ and ‘‘HFKDD.”
Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
The role of nuclear lamin B1 in cell proliferation and senescence
Shimi, T., Butin-Israeli, V., Adam, S. A., Hamanaka, R. B., Goldman, A. E., Lucas, C. A., Shumaker, D. K., Kosak, S. T., Chandel, N. S., & Goldman, R. D. (2011) · Genes & Development · doi:10.1101/gad.179515.111 · Cited by 547
Induction of apoptosis in HeLa cells by trans-activation-deficient p53.
Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., & Oren, M. (1995) · Genes & Development · doi:10.1101/gad.9.17.2170 · Cited by 545
Self-citationChinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., & Rehemtulla, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030545097 · Cited by 530
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Pavletich, N. P., Chambers, K. A., & Pabo, C. O. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2556 · Cited by 521
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
Self-citationCross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis
Gottlieb, T. M., Leal, J. F. M., Seger, R., Taya, Y., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205181 · Cited by 472
Self-citationBullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
Tetraploid State Induces p53-dependent Arrest of Nontransformed Mammalian Cells in G1
Andreassen, P. R., Lohez, O. D., Lacroix, F. B., & Margolis, R. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.5.1315 · Cited by 428
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation
Raveh, T., Droguett, G., Horwitz, M. S., DePinho, R. A., & Kimchi, A. (2001) · Nature Cell Biology · doi:10.1038/35050500 · Cited by 361
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
Bacus, S. S., Gudkov, A. V., Lowe, M., Lyass, L., Yung, Y., Komarov, A. P., Keyomarsi, K., Yarden, Y., & Seger, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204062 · Cited by 358
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., & Lund, A. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.109 · Cited by 352
“variant of the p53 gene.(22) Though the basal level of miR-34a was reduced in p53DD-expressing cells relative to the control cells expressing an empty vector, B-RAF induction in p53DD”
BackgroundSelf-citationMucin Gene Expression in Immortalized Human Corneal–Limbal and Conjunctival Epithelial Cell Lines
Gipson, I. K., Spurr-Michaud, S., Argu¨eso, P., Tisdale, A., Ng, T. F., & Russo, C. L. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0851 · Cited by 345
Rheinwald, J. G., Hahn, W. C., Ramsey, M. R., Wu, J. Y., Guo, Z., Tsao, H., De Luca, M., Catricalà, C., & O'Toole, K. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5157-5172.2002 · Cited by 338
c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release
Juin, P., Hueber, A.-O., Littlewood, T., & Evan, G. (1999) · Genes & Development · doi:10.1101/gad.13.11.1367 · Cited by 335
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328
“negative fashion (Shaulian et al. 1992).”
Self-citationZhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
p107 is a suppressor of retinoblastoma development in pRb-deficient mice
Robanus-Maandag, E., Dekker, M., van der Valk, M., Carrozza, M.-L., Jeanny, J.-C., Dannenberg, J.-H., Berns, A., & te Riele, H. (1998) · Genes & Development · doi:10.1101/gad.12.11.1599 · Cited by 320
p53-Dependent Transcriptional Repression of c-myc Is Required for G1 Cell Cycle Arrest
Ho, J. S. L., Ma, W., Mao, D. Y. L., & Benchimol, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7423-7431.2005 · Cited by 312
Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor
Dobner, T., Horikoshi, N., Rubenwolf, S., & Shenk, T. (1996) · Science · doi:10.1126/science.272.5267.1470 · Cited by 311
Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage
Cox, L. S., & Lane, D. P. (1995) · BioEssays · doi:10.1002/bies.950170606 · Cited by 287
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2
Stevenson, L. F., Sparks, A., Allende‐Vega, N., Xirodimas, D. P., Lane, D. P., & Saville, M. K. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601567 · Cited by 280
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
Rosen, E. M., Fan, S., Pestell, R. G., & Goldberg, I. D. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10257 · Cited by 268
Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., & Prives, C. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2565 · Cited by 265
Solution structure of the tetrameric minimum transforming domain of p53
Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265
Lessnick, S. L., Dacwag, C. S., & Golub, T. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00056-9 · Cited by 264
Minn, A. J., Boise, L. H., & Thompson, C. B. (1996) · Genes & Development · doi:10.1101/gad.10.20.2621 · Cited by 263
Lamin B1 fluctuations have differential effects on cellular proliferation and senescence
Dreesen, O., Chojnowski, A., Ong, P. F., Zhao, T. Y., Common, J. E., Lunny, D., Lane, E. B., Lee, S. J., Vardy, L. A., Stewart, C. L., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201206121 · Cited by 250
“, 1998), pBABE-hygro, and pBABE-hygro-p53DD (Shaulian et al., 1992) were obtained from B.”
BackgroundMethodInfluentialModulation of the Vitamin D3 Response by Cancer-Associated Mutant p53
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245
“Indeed, p53 mutations result not only in lossof tumor-suppressing activitiesby the mutant allele but also in trans-dominant inactivation of the remaining wild-type p53 (wtp53) (Shaulian et al., 1992).”
BackgroundSelf-citationNegative regulation of bcl-2 expression by p53 in hematopoietic cells
Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221
Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look
Soussi, T., & May, P. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0425 · Cited by 208
Single-chromosome Gains Commonly Function as Tumor Suppressors
Sheltzer, J. M., Ko, J. H., Replogle, J. M., Habibe Burgos, N. C., Chung, E. S., Meehl, C. M., Sayles, N. M., Passerini, V., Storchova, Z., & Amon, A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.004 · Cited by 201
“Trisomies 1, 13, 16, and 19, as well as matched euploid cell lines, were transduced with a dominant-negative allele of TP53 (p53dd; Shaulian et al., 1992), the E1a oncogene (which inhibits the Rb tumor suppressor, among several other cellular pathways; Gallimore and Turnell, 2001), the Large T…”
BackgroundInfluentialInhibition of p53 DNA binding by human papillomavirus E6 proteins
Lechner, M. S., & Laimins, L. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4262-4273.1994 · Cited by 195
Reciprocal down-regulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis
Drane, P., Bravard, A., Bouvard, V., & May, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204101 · Cited by 180
“Plasmid pCMVDD expresses a truncated mouse p53 including residues 1 ± 14 linked to the C-terminal fragment (residues 302 ± 390) (Shaulian et al., 1992). pCMVhumMnSOD contains the human MnSOD cDNA cloned into the pcDNA3 expression vector (Invitrogen).”
MethodSeluanov, A., Gorbunova, V., Falcovitz, A., Sigal, A., Milyavsky, M., Zurer, I., Shohat, G., Goldfinger, N., & Rotter, V. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1552-1564.2001 · Cited by 178
p53-dependent Down-regulation of Telomerase Is Mediated by p21
Shats, I., Milyavsky, M., Tang, X., Stambolsky, P., Erez, N., Brosh, R., Kogan, I., Braunstein, I., Tzukerman, M., Ginsberg, D., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402502200 · Cited by 133
Self-citationRuediger, R., Ruiz, J., & Walter, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05744-11 · Cited by 98
Kuzniewska, B., Rejmak, E., Malik, A. R., Jaworski, J., Kaczmarek, L., & Kalita, K. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00008-13 · Cited by 82
Tabach, Y., Milyavsky, M., Shats, I., Brosh, R., Zuk, O., Yitzhaky, A., Mantovani, R., Domany, E., Rotter, V., & Pilpel, Y. (2005) · Molecular Systems Biology · doi:10.1038/msb4100030 · Cited by 72
Wei, W., Jobling, W. A., Chen, W., Hahn, W. C., & Sedivy, J. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2859-2870.2003 · Cited by 68
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50
Metadata
- Authors
- Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1992-12
- Volume
- 12
- Issue
- 12
- Pages
- 5581-5592
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2124380422
- Cited by
- 342
- References
- 80
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.